TerrAscend (TSNDF) Liabilities and Shareholders Equity (2021 - 2026)
TerrAscend (TSNDF) reported Liabilities and Shareholders Equity of $549.1 million for Q1 2026, down 8.6% year-over-year from $600.7 million in Q1 2025, and down 1.49% quarter-over-quarter from $557.4 million in Q4 2025.
TerrAscend (TSNDF) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $549.1 million in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $549.1 million, down 8.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 billion (down 11.54% YoY), and the FY2025 annual result was $557.4 million, down 8.21% from the prior year.
- Liabilities and Shareholders Equity retreated to $549.1 million in Q1 2026 per TSNDF's latest filing, from $557.4 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $1.0 billion in Q1 2022 and troughed at $549.1 million in Q1 2026.
- A 5-year average of $688.9 million and a median of $660.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity grew 20.56% in 2022, then plunged 32.31% in 2023.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $701.6 million in 2022, then retreated by 5.0% to $666.5 million in 2023, then retreated by 8.9% to $607.2 million in 2024, then declined by 8.21% to $557.4 million in 2025, then slipped by 1.49% to $549.1 million in 2026.
- Business Quant data shows TSNDF's Liabilities and Shareholders Equity at $549.1 million in Q1 2026, $557.4 million in Q4 2025, and $555.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 2.27 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.35 Bn |
| 10 | TerrAscend | - | - | 34.60 Mn | 549.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 549.10 Mn |
| Dec 31, 2025 | 557.38 Mn |
| Sep 30, 2025 | 555.26 Mn |
| Jun 30, 2025 | 572.01 Mn |
| Mar 31, 2025 | 600.73 Mn |
| Dec 31, 2024 | 607.23 Mn |
| Sep 30, 2024 | 656.93 Mn |
| Jun 30, 2024 | 660.24 Mn |
| Mar 31, 2024 | 655.54 Mn |
| Dec 31, 2023 | 666.52 Mn |
| Sep 30, 2023 | 734.67 Mn |
| Jun 30, 2023 | 721.75 Mn |
| Mar 31, 2023 | 701.58 Mn |
| Dec 31, 2022 | 701.59 Mn |
| Sep 30, 2022 | 725.49 Mn |
| Jun 30, 2022 | 1.01 Bn |
| Mar 31, 2022 | 1.04 Bn |
| Dec 31, 2021 | 581.94 Mn |